<DOC>
	<DOCNO>NCT00499408</DOCNO>
	<brief_summary>RATIONALE : Vitamin D soy extract may effective lower prostate-specific antigen ( PSA ) level patient recurrent prostate cancer respond previous treatment . PURPOSE : This phase II trial study well give vitamin D together soy supplement work treat patient recurrent prostate cancer .</brief_summary>
	<brief_title>Vitamin D Soy Supplements Treating Patients With Recurrent Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Test response biochemically recurrent prostate cancer combination cholecalciferol ( i.e. , vitamin D ) soy isoflavones ( i.e. , soy extract ) fail definitive local therapy determine PSA response . OUTLINE : Patients receive oral cholecalciferol twice daily soy supplement ( i.e. , soy bar shake ) daily . Treatment continue 3-12 month absence disease progression unacceptable toxicity . Blood sample obtain baseline periodically study measure serum PSA , serum calcium , plasma cholecalciferol , plasma soy isoflavone level . Blood sample also analyze expression cholecalciferol receptor , p21 , p27 peripheral blood lymphocyte surrogate marker action cholecalciferol genistein . Protein expression assess immunoblot analysis cell lysates well quantitative polymerase chain reaction . Patients complete toxicity questionnaire month ass cholecalciferol soy supplementation toxicity symptoms hypercalcemia . After completion study therapy , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>Inclusion : Age &gt; 18 year Histologically confirm adenocarcinoma prostate Biochemical relapse follow definitive therapy ASTRO criterion ( PSA 3 consecutive rise measurement separate least one month ) minimum PSA ≥ 1.0 ng/mL PSA doubling time ≥ 6 month , demonstrate 3 PSA measurement obtain ≥ 2 month apart No hormonal therapy 6 month prior enrollment ECOG performance status 02 Life expectancy &gt; 3 month At least 2 year since prior definitive radiotherapy No concurrent cholecalciferol , calcium , soy supplement Absolute granulocyte count ≥ 1,000/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 2.0 mg/dL Total bilirubin ≤ 2.0 mg/dL Calcium &gt; 8.5 mg/dL &lt; 10.5 mg/dL Testosterone ≥ 150 ng/dL Exclusion : No clinically evident brain metastasis Concurrent cholecalciferol , calcium , soy supplement Concurrent chemotherapy nonstudy drug Serious medical illness would limit survival &lt; 3 month , psychiatric condition would preclude give informed consent Other malignancy except nonmelanoma skin cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient diseasefree past 5 year Active , uncontrolled bacterial , viral , fungal infection Hemorrhagic disorder Evidence metastatic disease bone scan CT scan History hypercalcemia More History exposure phytotherapeutics , include PCSPES Saw Palmetto , within last year .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>